Lexaria Bioscience Corp. · NASDAQ:LEXX
Lexaria Bioscience — Investor Presentation (July 2019)
27 slides from Lexaria Bioscience's investor presentation, July 2019
Slide 1: Lexaria Bioscience Corp. Drug Delivery Platform Innovator
Lexaria Bioscience Corp. LXX:CSE | LXRP:US Drug Delivery Platform Innovator Investor Presentation July 2019 LexariaBioscience.com 1
Slide 2: Disclaimer
Disclaimer This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company make
Slide 3: About Our Businesses
About Our Businesses EXISTING BUSINESS VERTICALS PENDING BUSINESS VERTICALS • World’s first ingestible nicotine products • An alternative to traditional smoking/vaping, gum • Next-gen formulations for PDE5 inhibitors, and patch nicotine based products NSAIDs, Vitamins, Hormones, and more • High bioa
Slide 4: US Cannabis Market
US Cannabis Market Over $1 Trillion Combined Market Size Cannabis/Hemp Pharma Nicotine 4 4
Slide 5: Achievements & Catalysts
Achievements & Catalysts Cannabis Nicotine (Non-Smoking Alternative) • Commercializing oral cannabinoid delivery that is up to 811% • Creating the world’s best ingestible/oral nicotine more effective than ingesting generic cannabinoids product • Cannabis/Hemp is a growing market with proven consumer
Slide 6: Patented Technology Benefits
Patented Technology Benefits Increases Masks unwanted Improves Increases Simple and brain taste speed of onset bioavailability cost effective absorption Eliminates the Effects are felt within Equates that of Animal testing Easy to implement need for sugar- 10-20 min (vs. 60-120 less healthy confirms
Slide 7: DehydraTECH Patent Portfolio
DehydraTECH™ Patent Portfolio Method of use & Composition of matter claims • Cannabinoids (CBD, THC) ~60 11 • • Nicotine (and its analogs) NSAIDs Patent Applications Patents Granted • Fat soluble vitamins 10 6 USA Multiple dosage forms - foods, liquid emulsions, tablets, capsules Patent Families 5 A
Slide 8: Cannabinoids | THC | CBD Oral Delivery
Cannabinoids | THC | CBD Oral Delivery 8 8
Slide 9: Non-Flower Consumption Continues To Gain Market Share
Non-Flower Consumption Continues To Gain Market Share US FLOWER VS. NON-FLOWER CONSUMPTION CANADA: CANNABIS SOLD TO CLIENTS IN 2018 (kgs) Colorado Oregon California 3734 4406 4124 4310 4391 4455 Non- 34 38 41 46 46 flower 56 56 57 60 Market share % 66 62 59 54 54 44 44 43 40 Apr May Jun Jul Aug Sept
Slide 10: Lexaria's DehydraTECH Technology is Faster and More Effective
Lexaria’s DehydraTECHTM Technology is Faster and More Effective Methods of Cannabinoid Consumption 1. Inhalation CASE STUDY: TurboCBD™ - Lexaria’s Oral CBD Product • High bioavailability (~32%), harmful to Lungs • 90mg DehydraTECH dose vs. Competitor 100mg dose 2. Sub-lingual (under tongue) • Compet
Slide 11: Case Study: TurboCBD - Clinically Proven Blood/Body Response Benefits
Case Study: TurboCBD™ - Clinically Proven Blood/Body Response Benefits • 2018 European human 80 Turbo 90mg clinical study (n=12) 70 ** 90mg placebo ** • Double-blind, 90 mg CBD dose Venous plasma concentration (ng/mL) 60 • 317% more CBD delivered 50 ≤ 30 min (95% CI, p=0.051). 40 • Higher CBD delive
Slide 12: Strategy and Execution
Strategy and Execution Business Model Our Progress Innovation & research • New product development Lexaria’s technology is highly scalable and is • New patent applications & existing patent pursuit demonstrating commercial traction • Clinical trials • Commercial partners – Demonstration products • 2
Slide 13: Lexaria Nicotine Oral Nicotine Delivery Forms
Lexaria Nicotine Oral Nicotine Delivery Forms LexariaNicotineCo.com Investor Presentation 13 13
Slide 14: Nicotine Market Overview
Nicotine Market Overview • Smoking is the world’s leading cause of preventable death • Lexaria to provide the world’s first • FDA has a comprehensive regulatory plan to ingestible shift the trajectory of tobacco-related disease 1.1 billion nicotine product and death smokers globally in a $990B globa
Slide 15: Nicotine Commercial Strategy
NICOTINE COMMERCIAL STRATEGY About Altria Group (NYSE: MO) Altria #1 Dominant Market Share • Market Cap: $91B USD as of July 5 2019 • Smokeless/non-combustible products represent the fastest growing portion of Altria’s revenue • Altria owns a portfolio of global tobacco brands including: Phillip Mor
Slide 16: The World's First Ingestible Nicotine Product
The World’s First Ingestible Nicotine Product Nicotine Studies Nicotine Blood-Brain-Barrier Results Summary • Have completed two PK studies with nicotine to date: Control DehydraTECH™ % • 17LEXAP1 (04/18) (10 mg/Kg) Improvement (10 mg/Kg) • 48% improvement in peak Cmax nicotine delivery to the blood
Slide 17: Lexaria's Product Offers Significant Improvements
Lexaria’s Product Offers Significant Improvements Caliper SC / Generic Industry Lexaria DehydraTECHTM VESIsorb OLEOTM Ripple Sugar/additives not Flavouring Sugars and artificial Taste Flavouring added Flavouring added required added flavors required Measurable blood levels in 40-75 minute Rapid 2 mi
Slide 18: Why Invest In Lexaria Bioscience?
Why Invest In Lexaria Bioscience? • Partnered with Altria Group, one of the largest Trading symbol: LXX:CSE, LXRP:OTCQX companies in the world, for non-smokable new Shares O/S: 78M nicotine alternatives/delivery methods Fully Diluted: 86M o Agreement to pay royalties Price (07/10/19): C$1.09 Insider
Slide 19: Presentation Appendices
Presentation Appendices 19 19
Slide 20: How Does DehydraTECH Work?
How Does DehydraTECH™ Work? Process: Results: 1) Combine API and Fatty Acid Oil Fatty acids are believed to block and shunt bound + APIs away from bitter taste receptors* Cannabidiol LCFA: sunflower oil Lipids enable gastric protection and rapid passage** 2) Apply to food/carrier particles Small int
Slide 21: Clinically Proven PK/PD Performance Gains - TurboCBD
Clinically Proven PK/PD Performance Gains - TurboCBD™ • 2018 European human 80 Turbo 90mg clinical study (n=12) 70 ** 90mg placebo ** • Double-blind, 90 mg CBD dose Venous plasma concentration (ng/mL) 60 • 317% more CBD delivered 50 ≤ 30 min (95% CI, p=0.051). 40 • Higher CBD delivery Ψ throughout e
Slide 22: DehydraTECH Outperforms Conventional MCT Formulations
DehydraTECH™ Outperforms Conventional MCT Formulations 334% higher Cmax over 60 min. 475% more CBD Delivered @ 15 min. Plasma cannabidiol (CBD) concentration in 10 male Sprague-Dawley rats administered at 25mg per kg of bodyweight. Delivery of CBD into the bloodstream was monitored over a 60-minute
Slide 23: 17LEXAP1 Nicotine PK Results
17LEXAP1 Nicotine PK Results 48% improvement 1,160% faster delivery 560% higher brain levels in peak Cmax nicotine of equivalent peak Cmax of nicotine where delivery to the quantities of nicotine to nicotine effects are bloodstream relative to the bloodstream than focused, compared to controls. achi
Slide 24: 17LEXAP1 Additional Findings of Interest
17LEXAP1 Additional Findings of Interest • Lower urine levels of nicotine excreted than controls (indicating enhanced nicotine activity and bioavailability over the course of the study); • Lower liver metabolite levels (hydroxycotinine, nicotine N’-oxide and cotinine) in the bloodstream than control
Slide 25: 18LEXAP1 Nicotine PK Results
18LEXAP1 Nicotine PK Results DehydraTECH™ Control Formulation Formulation (nicotine (nicotine polacrilex 10 polacrilex 10 % 90% 70% more mg/Kg) mg/Kg) 94% Improvement pValue more nicotine Average Nicotine Blood Level 0- more nicotine delivered 15 min overall (ng/mL) 203 120 nicotine 70 0.0004 delive
Slide 26: Key Executives
KEY EXECUTIVES Chris Bunka John Docherty, M.Sc. Dr. Edward Ergenzinger Chairman & CEO Director & President Chief Legal, SVP Innovation Serial entrepreneur involved in Specialist in development of drug U.S. licensed patent attorney, several private and public delivery technologies. Doctorate in Neuro
Slide 27: Key Advisors
KEY ADVISORS Dean of the Graduate School and Professor in the Professor, Psychology and Neuroscience, at Wake Departments of Neurobiology and Anatomy and the Forest University, and is past president of the Institute for Regenerative Medicine at Wake Forest Society for Psychophysiological Research Un
Lexaria Bioscience — Investor Presentation (July 2019) on 6ix